2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pain
5
Colorectal Neoplasms
5
Neoplasms
4
Breast Neoplasms
4
Stomatitis
3
Neoplasm Metastasis
3
Adenoma
3
Urologic Neoplasms
2
Stomach Neoplasms
2
Mucositis
2
Insulin Resistance
2
Head and Neck Neoplasms
2
Vulvodynia
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
Melanoma
1
MRSA Colonization
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
Cystectomy
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Therapeutics
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled